Impact of aristolochic acid exposure on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy

被引:16
|
作者
Zhong, Wenlong [1 ,2 ,3 ]
Zhang, Lei [1 ,2 ,3 ]
Ma, Jiajian [4 ]
Shao, Shan [5 ]
Lin, Rongcheng [1 ,2 ,3 ]
Li, Xuesong [1 ,2 ,3 ]
Xiong, Gengyan [1 ,2 ,3 ]
Fang, Dong [1 ,2 ,3 ]
Zhou, Liqun [1 ,2 ,3 ]
机构
[1] Peking Univ, Hosp 1, Dept Urol, 8 Xishiku St, Beijing 100034, Peoples R China
[2] Peking Univ, Inst Urol, Beijing, Peoples R China
[3] Natl Urol Canc Ctr, Beijing, Peoples R China
[4] Peking Univ, Hlth Sci Ctr, Beijing, Peoples R China
[5] Peking Univ, Neurosci Res Inst, Beijing, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2017年 / 10卷
关键词
aristolochic acid; urothelial carcinoma; upper urinary tract; radical nephroureterectomy; survival; prognosis; UPPER URINARY-TRACT; CELL-CARCINOMA; NEPHROPATHY; CANCER; BLADDER; SERIES;
D O I
10.2147/OTT.S148641
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective: To investigate the effect of aristolochic acids (AA) exposure, including exposure duration and years since last exposure, on oncologic outcomes of patients with upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). Methods: We retrospectively collected clinicopathologic and AA exposure variables for 942 UTUC patients treated with RNU between 1999 and 2014 in a high-volume center of China. AA exposure duration was categorized as (> 3 vs <= 3 years) and time since last AA exposure to surgery as (>5 vs <= 5 years). Results: A total of 856 patients (90.9%) had none or possible AA exposure and 86 patients (9.1%) had credible AA exposure history. Among the 86 patients, 57 (66.3%) had AA exposure for <= 3 years and 29 (33.7%) had exposure for >3 years. The median follow-up duration was 60 months. By multivariate analysis, AA exposure history was significantly associated with cancer specific survival (hazard ratio [HR]: 0.43, p=0.02), intravesical recurrence (IVR) (HR: 2.25, p<0.001) and contralateral UTUC recurrence (HR: 2.71, p=0.001). After adjusted for the effects of standard clinicopathologic characteristics, exposure duration was independent risk factor for subsequent IVR (exposure duration <= 3 years vs none/possible AA, HR: 1.87, p=0.009; exposure duration >3 years vs none/possible AA, HR: 3.07, p<0.001), but not for cancer-specific survival (p=0.06). Also, of those patients who had AA exposure, those having exposure within 5 years prior to RNU did not differ from patients having last exposure >5 years ago regarding cancer specific mortality (p=0.67) and IVR (p=0.54). Conclusion: AA exposure was associated with worse cancer-specific survival, higher rate of IVR and contralateral UTUC recurrence of UTUC treated with RNU. The association between AA exposure and IVR seems to be time-dependent. Exposure cessation >5 years prior to RNU cannot mitigate the impact of AA on the UTUC prognosis.
引用
收藏
页码:5775 / 5782
页数:8
相关论文
共 50 条
  • [21] Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma
    Martini, Alberto
    Lonati, Chiara
    Nocera, Luigi
    Fallara, Giuseppe
    Raggi, Daniele
    Herout, Roman
    Zamboni, Stefania
    Ploussard, Guillaume
    Predere, Benjamin
    Mattei, Agostino
    Simeone, Claudio
    Krajewski, Wojciech
    Simone, Giuseppe
    Soria, Francesco
    Gontero, Paolo
    Roupret, Morgan
    Montorsi, Francesco
    Briganti, Alberto
    Shariat, Shahrokh F.
    Necchi, Andrea
    Moschini, Marco
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (04): : 451 - 459
  • [22] Impact of perioperative blood transfusion on oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma.
    Bagrodia, Aditya
    Kaffenberger, Samuel D.
    Vacchio, Michael J.
    Murray, Katie S.
    Winer, Andrew G.
    Cha, Eugene K.
    Sankin, Alexander
    Dalbagni, Guido
    Coleman, Jonathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [23] Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma
    Pignot, Geraldine
    Colin, Pierre
    Zerbib, Marc
    Audenet, Francois
    Soulie, Michel
    Hurel, Sophie
    Delage, Francky
    Irani, Jacques
    Descazeaud, Aurelien
    Droupy, Stephane
    Rozet, Francois
    Phe, Veronique
    Ruffion, Alain
    Long, Jean-Alexandre
    Crouzet, Sebastien
    Houlgatte, Alain
    Bigot, Pierre
    Guy, Laurent
    Fais, Pierre-Olivier
    Roupret, Morgan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 23.e1 - 23.e8
  • [24] Impact of relapse site on oncological outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma
    Yamashita, Shinichi
    Ito, Akihiro
    Mitsuzuka, Koji
    Kawasaki, Yoshihide
    Shintaku, Ichiro
    Tochigi, Tatsuo
    Soma, Fumihiko
    Namima, Takashige
    Katoh, Shinnosuke
    Ota, Shozo
    Kyan, Atsushi
    Orikasa, Kazuhiko
    Takeda, Atsushi
    Numahata, Kenji
    Aizawa, Masataka
    Ioritani, Naomasa
    Adachi, Hisanobu
    Kawamorita, Naoki
    Kaiho, Yasuhiro
    Arai, Yoichi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [25] Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy
    Hurel, Sophie
    Roupret, Morgan
    Ouzzane, Adil
    Rozet, Francois
    Xylinas, Evanguelos
    Zerbib, Marc
    Berod, Alexis Arvin
    Ruffion, Alain
    Adam, Emilie
    Cussenot, Olivier
    Houlgatte, Alain
    Phe, Veronique
    Nouhaud, Francois-Xavier
    Bensadoun, Henri
    Delage, Francky
    Guillotreau, Julien
    Guy, Laurent
    Karsenty, Gilles
    De La Taille, Alexandre
    Colin, Pierre
    BJU INTERNATIONAL, 2013, 111 (08) : 1199 - 1207
  • [26] Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma
    Bagrodia, Aditya
    Kaffenberger, Samuel
    Winer, Andrew
    Murray, Katie
    Vacchio, Michael
    Zheng, Junting
    Ostrovnaya, Irina
    Bochner, Bernard H.
    Dalbagni, Guido
    Cha, Eugene K.
    Coleman, Jonathan A.
    WORLD JOURNAL OF UROLOGY, 2018, 36 (04) : 645 - 653
  • [27] Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma
    Aditya Bagrodia
    Samuel Kaffenberger
    Andrew Winer
    Katie Murray
    Michael Vacchio
    Junting Zheng
    Irina Ostrovnaya
    Bernard H. Bochner
    Guido Dalbagni
    Eugene K. Cha
    Jonathan A. Coleman
    World Journal of Urology, 2018, 36 : 645 - 653
  • [28] Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma
    Bagrodia, Aditya
    Kuehhas, Franklin E.
    Gayed, Bishoy A.
    Wood, Christopher G.
    Raman, Jay D.
    Kapur, Payal
    Derweesh, Ithaar H.
    Bensalah, Karim
    Sagalowsky, Arthur I.
    Shariat, Shahrokh F.
    Lotan, Yair
    Margulis, Vitaly
    UROLOGY, 2013, 81 (05) : 972 - 977
  • [29] Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy
    Sophie Hurel
    Morgan Rouprêt
    Thomas Seisen
    Eva Comperat
    Véronique Phé
    Stéphane Droupy
    François Audenet
    Géraldine Pignot
    Xavier Cathelineau
    Laurent Guy
    Olivier Cussenot
    Adil Ouzzane
    Gregory Bozzini
    Laurent Nison
    Alain Ruffion
    Pierre Colin
    World Journal of Urology, 2015, 33 : 335 - 341
  • [30] Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy
    Hurel, Sophie
    Roupret, Morgan
    Seisen, Thomas
    Comperat, Eva
    Phe, Veronique
    Droupy, Stephane
    Audenet, Francois
    Pignot, Geraldine
    Cathelineau, Xavier
    Guy, Laurent
    Cussenot, Olivier
    Ouzzane, Adil
    Bozzini, Gregory
    Nison, Laurent
    Ruffion, Alain
    Colin, Pierre
    WORLD JOURNAL OF UROLOGY, 2015, 33 (03) : 335 - 341